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Commitment to scientific enquiry has led to research into
human embryo stem cells for therapeutic goals. However,
many ethical and legal issues are raised and the question as to
whether or not to proceed with human cloning as a means to
therapeutic ends is a morally serious and vexing one.1 On the
one hand, the medical profession and the public grapple with
the promise that such research could lead to important
knowledge that could benefit science and society at large. On
the other hand, the moral complexities associated with such
research require consideration as to whether there could be
compelling reasons to limit or prohibit research in this field
entirely.2
This paper briefly describes the sources of stem cells and the
various forms of cloning. Ethical issues central to this debate
are discussed. Disparities in legal systems internationally with
regard to embryonic stem cell research are described, and the
South African legal standpoint on the issue will be presented. 
Sources of stem cells and therapeutic
cloning — scientific backdrop to the
debate
Stem cells
Stem cells are tissue precursor cells that have the ability to self-
renew and differentiate into more specific adult cells required
in the body.3-6 They are found at all stages of development and
in most tissues.3 Early human embryos (5 - 6-day-old
blastocysts) comprise an outer cell layer from which the
placenta develops, and an inner cell mass of in the region of
200 cells which gives rise to the fetus. This inner cell mass is
the source of embryonic stem cells. 
Totipotent stem cells are found in the embryo up to the 
16-cell stage. These cells have the ability to form an entirely
independent human being if placed in the uterus. The inner
cell mass of the late blastocyst stage of the embryo comprises
pluripotent stem cells, which have a limited ability to give rise
to any type of specialised cell.7 According to the South African
Medical Research Council (MRC), research involving the use of
totipotent stem cells is strictly prohibited. The MRC’s view on
pluripotent cells is that they are ‘extraordinarily interesting to
study’.8
Somatic stem cells are more committed or multipotent. Their
differentiation is restricted to only one or a few tissue lineages.
Although these cells have the ability to self-renew indefinitely,
in general their frequency and versatility decline with
differentiation. Self-renewal is especially low in mature organs.3
Potential sources of stem cells are fetal tissue that becomes
available after an abortion, excess embryos from assisted
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Therapeutic embryonic stem cell research raises a number of
ethical and legal issues. The promised benefits are new and
important knowledge of human embryological development,
gene action, and the production of transplantable tissue and
organs that could be effective in reversing or curing currently
irreversible disease processes. However, this research involves
the deliberate production, use, and ultimate destruction of
cloned embryos, hence re-awakening the debate on the moral
status of the embryo. Other moral anxieties include the
possibility that women (as donors of ova) would be exploited,
that this research would land on the slippery slope of
reproductive cloning, and that promises made too early could
lead to false hope among sick patients. It also raises the
question of intellectual and actual property rights in human
cell lines and the techniques by which they are produced.
Review of legal systems internationally reveals that there is
no global consensus on therapeutic embryonic stem cell
research. Legal considerations are very much influenced by
ethical deliberations on the moral status of the embryo. The
South African parliament is promulgating legislation
permitting therapeutic cloning, thereby demonstrating a
commitment by the state to act in the best interests of patients
and of regenerative medicine.
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reproductive technologies, embryos created through in vitro
fertilisation specifically for research purposes, and embryos
created asexually as a result of the transfer of a human somatic
cell nucleus to a denucleated ovum.5 Other sources of stem cells
are umbilical cord blood and bone marrow.9 In addition, neural
stem cells, haematopoietic stem cells (HSCs) and mesenchymal
stem cells (MSCs) can be harvested from fetal blood and fetal
tissue.10. Adult stem cells have been isolated from bone marrow,
muscle, blood, liver and brain, where they function in tissue
repair.3 Adult bone marrow is also an easily accessible source of
MSCs, which differentiate under specific laboratory conditions
into fat, bone, cartilage, nerves and muscle.11 Adult stem cells
have so far been used for bone marrow transplants, skin grafts
and the treatment of leukaemias.12 Harvesting of adult stem cells
is unlikely to cause controversy. However, the ability of these
cells to reproduce is restricted, limiting their use for therapies.13
Cloning
‘Clone’ means a precise genetic copy of a life form.8 The cloning
of animal and human genes has been practised for many years.14
Cloning at a molecular level involves the copying of DNA
fragments containing genes and amplifying these in a host cell.
The copying of somatic cells by growing them in culture results
in cellular cloning. Utility here would be for the testing and
production of new medical products.14 Blastomere separation
involves the splitting of the 2 - 8-cell embryo soon after
fertilisation. Each of these totipotent cells is genetically identical.
In nuclear transplantation cloning, the nucleus of a somatic cell
is placed into an ovum, the nucleus of which has been removed.
The National Health Bill of the Republic of South Africa15
defines reproductive cloning of a human being as the
manipulation of genetic material in order to achieve the
reproduction of a human being and includes nuclear transfer or
embryo splitting for such purpose. Therapeutic cloning is
defined as the manipulation of genetic material from adult,
zygote or embryonic cells in order to alter the function of cells or
tissues for therapeutic purposes. 
The method of obtaining and culturing human embryonic
cells indefinitely was described in 1998.16 Just 2 years earlier,
methods for the cloning of adult mammals using nuclear
replacement techniques were reported in the scientific
literature.17 More recently, scientifically unsubstantiated claims of
successfully cloned children have been reported in the press.18-20
The ethical debate — an overview
There have been mixed reactions to the prospect of cloning for
biomedical research. It is supported by some for its medical
promise, but opposed by others who view it as an intentional
exploitation and destruction of nascent human life created
specifically for research purposes, thereby undermining human
dignity. 
The moral status of the embryo
Society remains divided on the highly controversial issue of the
moral status of, and what is owed to, developing human life.
This divergence of opinion also poses an impediment towards
arriving at a solution on what is owed to the cloned embryo.
The moral status of the embryo was deliberated extensively but
not resolved during the abortion debate. Neither was it
unravelled during subsequent debates on certain forms of
assisted reproductive technologies. The current debates on stem
cell research are unlikely to lead to a solution on what is due to
the embryo, as the essence of the debate remains unchanged and
no new arguments have been forwarded.21
A review of comparative law on abortion and assisted
reproductive technologies demonstrates the adoption of a
middle position. The extreme views that embryos have no moral
status and hence command no respect or that embryos have the
same moral status as born human beings are not advocated. For
instance, in South Africa an embryo has no legal standing until it
is born alive.22 However, once it is born alive it retains all its
rights including those that were violated while it was in utero.23 
Historically, sacrifice of developing human life has been
accepted to benefit others. In the practice of obstetrics, the
pregnant woman’s welfare is paramount. A known complication
of pregnancy is severe hypertension requiring immediate
delivery despite a slim chance of fetal survival. In the past, some
cases of obstructed labour were managed by fetal craniotomy.
Even where the woman’s life is not endangered, fetocide is
practised in order to optimise survival for others.24 It has been
accepted clinical practice to forfeit one life in order to allow for
the survival of others.25 Selective abortion may follow as a
consequence of prenatal diagnosis. Here the burdens associated
with infants surviving with severe abnormalities are carefully
balanced against the benefits of selective abortion to the
potential person, the family and society. Hence, moral precedent
already exists for subordinating nascent for more developed
human life. These principles are also embodied in the Choice on
Termination of Pregnancy Act26 which allows for terminations of
pregnancy even in the third trimester.  Accordingly, it can be
stated that in ethics and in the law, the embryo is not owed the
same protections and rights as a born human being.
Deliberate creation of embryos for use in research
It has been suggested that the use of spare embryos from
completed assisted reproductive technology (ART) cycles would
be less problematic.4 Arguments regarding the moral status of
the embryo would apply equally to both types of embryos.
Substantive argument can be made for the use of cloned
embryos to avoid immune rejection problems.
Reproductive cloning – a slippery-slope issue
The line between therapeutic cloning and reproductive cloning
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is quite clear. Despite the possibility that the technology
generated could be misused, appropriate legislation permitting
the former and proscribing the latter could be instituted.1 South
Africa has moved ahead on this.  
Exploitation of women
Cloning for biomedical research would require ova from women
donors. This raises concerns regarding the exploitation of
women and re-opens debate on the co-modification of human
body parts.27 Hormonal treatment for the stimulation of the
ovaries in order to produce excess ova is not without risk.
However, the ethical codes regulating research on human
participants are protective against harms. It is expected that
intensive ethical review of proposals for cloning for biomedical
research purposes would optimise subject protection.     
Using ova from other species in creating stem cells by nuclear
transfer techniques may be a way to overcome the problems of
ova scarcity and the ethical issues associated with using women
donors in this research. This possibility has met with scepticism
from scientists despite an American firm, Advanced Cell
Technology, patenting such a technique.28 In addition, ethical
problems associated with the moral status of the hybrid embryo
may be easier to overcome than ethical problems associated with
the moral status of the human embryo. 
Raising expectations in seriously ill patients
Society has been promised extensive and instant benefits from
stem cell research. It is morally unacceptable to raise false hope
in gravely ill people. Researchers need to be honest in their
public presentation of the benefits of stem cell research with
regard to time intervals between theoretical possibility and
clinical practice.4
Intellectual property rights
An additional ethical concern is that the techniques whereby
human cell lines are produced and the results of the research
could be patented, obstructing access to care. Apart from the
concerns over transactional costs, there are questions as to
whether the human body can be the subject of property rights
and whether the human genome is actually the common
heritage of mankind.8 Legislation could be invoked regulating
and preventing such patents.
Embryo stem cell research — medical possibilities
and ethical imperatives
Chronic debilitating degenerative diseases including those of the
brain (Parkinson’s and Alzheimer’s disease), pancreas (diabetes),
liver (hepatitis), joints (rheumatoid arthritis), heart, lungs and
kidneys and spinal cord injuries cause immense suffering to
patients, their families and society. They also shorten lifespan
and limit activity. Embryonic stem cell research may offer unique
ways of investigating and possibly treating many of these
diseases.2,29 Creating embryos using nuclei from individuals
carrying genetic mutations predisposing them to particular
diseases could be used to develop an improved understanding
and treatment of the diseases. Embryonic stem cells could
populate unhealthy or dead tissue, differentiate, regenerate
diseased tissue and compensate for loss of function or restore
normal function.2 Moreover, embryonic stem cells could benefit
patients requiring transplants. The demand for organs for
transplant procedures has steadily increased in recent times,
with currently over 84 000 people waiting for organ transplants
in the USA. The situation is worse in developing countries such
as South Africa where not many people donate organs.12 A
further benefit of embryo stem cell research could be genetic
therapy for genetic diseases as a result of the combination of
cloning techniques and genetic manipulation.30 Healing of burns
and fractures could be accelerated. Cystic fibrosis, muscular
dystrophy and other genetic diseases could be cured by using
stem cells to deliver the missing protein or gene to target tissue.3
So far, embryonic stem cells have been differentiated into
functional neurons and beating cardiac muscle in the
laboratory,31 and MSCs have been given to children with
osteogenesis imperfecta. In the latter, bone density has been
noted to improve, and fracture frequency has reduced.32 The
possible medical gains of embryonic stem cell research are
immense, hence an ethical imperative to proceed with work in
this area. 
Embryo stem cell research — regulatory
and policy issues
In law the destruction of an embryo is not murder because the
embryo is not regarded as a person.22 Widely held philosophical
and moral views hold that the status of a person requires further
development, such as a nervous system capable of sentience. By
day 14, the primitive streak, the first sign of development of the
nervous system may be observed. Based on this, some countries
permit research for specified purposes on embryos of less than
14 days. South Africa has opted for the 14-day limit.15 
Reproductive cloning has been banned in many countries.
Some countries have banned all forms of cloning without
making a distinction between reproductive and therapeutic
cloning. In the USA, Congress has banned federal funding for
human embryo research. Research using private funds has not
been proscribed.33 Although the laws making their way through
federal and state legislatures all aim to criminalise reproductive
cloning, different approaches to therapeutic cloning have been
taken.34 Germany, Austria, Ireland, Denmark and France prohibit
research on embryos requiring their destruction.12 In Britain,
research for infertility, contraception, birth defects and stem cell
therapy is permitted on embryos until day 14 of development.
Although reproductive cloning is banned under the Human
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Fertilisation and Embryology (HFE) Act of 1990,35 stem cell
research using embryos was approved by an extension of the
HFE Act in 2001.13 In Australia, legislation varies between the
states, with embryo research being banned in Victoria, but
permitted in New South Wales and Queensland.33 It is interesting
to note that the USA, Germany and Victoria in Australia permit
work on embryos imported from other countries.12,33
In South Africa, legislation prohibiting genetic manipulation
of gametes and zygotes outside the body, and hence cloning,
has been in effect for the last few decades.36 The MRC in South
Africa recommends that for the present, cadaveric fetal tissue
and embryos remaining after completion of infertility
treatments should be the only source of embryonic stem cells
for the purposes of research.8 It is the opinion of the authors
that these recommendations are too restrictive and serve to
stifle scientific progress aiming to benefit patients with
irreversible and debilitating disease. Moreover, researchers in
South Africa have a constitutional right to ‘freedom of scientific
research’.37 Therefore, the freedom to research embryonic stem
cells can only be restricted if such restrictions are ‘reasonable
and justifiable in an open and democratic society based on
human dignity, equality and freedom.38 Given the conflicting
approaches to the law in other democratic countries,12 it may be
difficult to show that such restrictions are unreasonable.
However, the state is required to use the least restrictive means
to achieve its objectives when infringing constitutional rights38
and it could be for this reason that the national government
reviewed its stance on the matter.  Section 62(4) of the National
Health Bill,15 published in the Government Gazette in August
2002, allows for therapeutic cloning and embryo stem cell
research on less than 14-day-old embryos. However, very strict
regulatory criteria have to be fulfilled, including authorisation
by the Minister of Health for work in this field. Section 62(1)
outlaws reproductive cloning. 
Conclusion
The process of healing has been accelerated as a result of the
tremendous advances in biomedical research. Restrictions on
the rights and freedom to research should only be for the most
meaningful reasons, and as least restrictive as possible, in order
to prevent damage to the scientific undertaking. Removing
unreasonable prohibitions against embryonic stem cell research
and encouraging work in this direction allows for society to
benefit from the wealth of knowledge that will be created. The
South African parliament has promulgated legislation
permitting therapeutic cloning, thereby demonstrating a
commitment by the state to act in the best interests of patients
and of regenerative medicine (Act No. 61 of 2003). Here, there
has been a partnership and not polarity between scientists and
regulators. Legislative imprudence has not impeded scientific
wisdom.  Clearly, the message from South Africa is that it will
be unreasonable to prohibit research using the technology of
somatic nuclear transfer for therapeutic cloning.  
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